Comparison of Short-Term DAPT and Long-Term DAPT on the Prognosis of PCI Patients: A Meta-Analysis of Randomized Controlled Trials

Comparison of Short-Term DAPT and Long-Term DAPT on the Prognosis of PCI Patients: A Meta-Analysis of Randomized Controlled Trials

Background: Dual antiplatelet therapy (DAPT) is the primary medication for patients after percutaneous coronary intervention (PCI). However, the best DAPT duration is still controversial. This systematic review and meta-analysis aims to assess the safety and effectiveness of short-term (3–6 months)...

Full description

Bibliographic Details
Main Authors:	Jiaxin Yang, Yaodong Ding, Rui Wang, Kexin Wang, Xiaoli Liu, Hua Shen, Yan Sun, Hailong Ge, Zhe Fang
Format:	Article
Language:	English
Published:	IMR Press 2022-09-01
Series:	Reviews in Cardiovascular Medicine
Subjects:	dual antiplatelet therapy duration p2y12 receptor inhibitor percutaneous coronary intervention (or pci) drug-eluting stents (or des)
Online Access:	https://www.imrpress.com/journal/RCM/23/10/10.31083/j.rcm2310326

Similar Items

Long‐Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second‐Generation Drug‐Eluting Stents: The Veterans Affairs Extended DAPT Study
by: Scott Kinlay, et al.
Published: (2023-01-01)

The effects of dual antiplatelet therapy (DAPT) adherence on survival in patients undergoing revascularization and the determinants of DAPT adherence
by: Shuqi Zhang, et al.
Published: (2022-05-01)

Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with chronic coronary artery disease (CAD) - current state of knowledge and perspective for further research
by: Hubert Bochenek, et al.
Published: (2025-02-01)

Double Trouble: Interrupting DAPT and COVID-19
by: Mihăilă Theofana, et al.
Published: (2022-06-01)

Contrastive learning with transformer for adverse endpoint prediction in patients on DAPT post-coronary stent implantation
by: Fang Li, et al.
Published: (2025-01-01)

Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
by: Kwan Yong Lee, et al.
Published: (2022-11-01)

Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI
by: Hao-Yu Wang, et al.
Published: (2020-07-01)

Dynamic Prognosis Prediction for Patients on DAPT After Drug‐Eluting Stent Implantation: Model Development and Validation
by: Fang Li, et al.
Published: (2024-02-01)

Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-Dragon Registry)
by: Rafał Januszek, et al.
Published: (2022-04-01)

Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2019-01-01)

Premature Discontinuation of Dual Antiplatelet Therapy After Coronary Stenting in Veterans: Characteristics and Long‐Term Outcomes
by: Scott Kinlay, et al.
Published: (2021-05-01)

A comparison of safety and efficacy between long-term DAPT and intensive statins combined with short-term DAPT for acute ischemic stroke
by: Ting Deng, et al.
Published: (2023-04-01)

Validation of the DAPT score in large-scale consecutive and contemporary patients population in the real world
by: Guofeng Gao, et al.
Published: (2021-11-01)

Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI
by: Hao-Yu Wang, et al.
Published: (2021-05-01)

Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
by: Liang Dong, et al.
Published: (2022-07-01)

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)
by: A. Mezier, et al.
Published: (2023-03-01)

Interim Results of the Basket of Real-World Randomised Clinical PRISM Trials for M’Sure-S, a Next-Generation Sirolimus-Eluting Stent, Versus Eliminator, an Everolimus-Eluting Stent
by: Marc Silvestri, et al.
Published: (2018-09-01)

FFR guided PCI on long coronary lesions: 2-year clinical results with 2nd or newer generation DES
by: Arvydas Baranauskas, et al.
Published: (2016-04-01)

The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation
by: Zhao J, et al.
Published: (2023-01-01)

Editorial: Reviews in bioresorbable scaffold
by: Vikrant Rai, et al.
Published: (2024-06-01)

Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation
by: Seung‐Jun Lee, et al.
Published: (2024-10-01)

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention
by: Hou L, et al.
Published: (2023-08-01)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
by: Charles E. Howard, et al.
Published: (2019-10-01)

Performance of the REACH, PARIS, BleeMACS, and PRECISE-DAPT scores for predicting 1-year bleeding events in patients undergoing coronary drug-eluting stent implantation
by: Si-Qi Lyu, et al.
Published: (2022-07-01)

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis
by: Ying Zeng, et al.
Published: (2024-02-01)

Case‐fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta‐analysis
by: Tobias Tritschler, et al.
Published: (2022-10-01)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
by: Iraj Jafaripour, et al.
Published: (2023-05-01)

Incidence of bleeding and performance of the PRECISE-DAPT score in predicting bleeding in patients on dual antiplatelet therapy after treatment for acute coronary syndrome in Kenya
by: Peter Mugo, et al.
Published: (2025-02-01)

How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?
by: Kongyong Cui, et al.
Published: (2022-05-01)

Can antiplatelet therapy after drug eluting stent become a problem?
by: Michele Romano
Published: (2009-03-01)

An epidural catheter removal after recent percutaneous coronary intervention and coronary artery stenting: Epidural catheter and antiaggregation therapy
by: Joksić Nikola, et al.
Published: (2016-01-01)

Short Versus Long-Term Dual Antiplatelet Therapy in Patients at High Bleeding Risk Undergoing PCI in Contemporary Practice: A Systemic Review and Meta-analysis
by: Nader Mankerious, et al.
Published: (2023-06-01)

Ten-year clinical outcomes of everolimus- and biolimus-eluting coronary stents vs. everolimus-eluting bioresorbable vascular scaffolds—insights from the EVERBIO-2 trial
by: Samir Bengueddache, et al.
Published: (2024-09-01)

Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients
by: Eleni M. Gamvroulas, et al.
Published: (2023-03-01)

Hemorrhagic stroke during the acute phase of myocardial infarction: a rare and difficult situation to manage
by: Abdelaziz Boudihi, MD, et al.
Published: (2023-03-01)

Gene Delivery from Stents for Prevention of In Stent Restenosis
by: Ilia Fishbein, et al.
Published: (2016-12-01)

Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends
by: Lili Tan, et al.
Published: (2023-05-01)

CABG Surgery Remains the best Option for Patients with Left Main Coronary Disease in Comparison with PCI-DES: Meta-Analysis of Randomized Controlled Trials
by: Michel Pompeu Barros Oliveira Sá, et al.

A more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: an Italian post-maRketing study (the CAESAR registry)
by: Giuseppe Tarantini, et al.
Published: (2024-01-01)

Impact of premature coronary artery disease on adverse event risk following first percutaneous coronary intervention
by: Tineke H. Pinxterhuis, et al.
Published: (2023-06-01)